| Field | Sense | Antisense |
| siRNA chemical modification | N6-ethyl-N6 2-Deoxyadenosine | N6-Ethyl-N6 2-Deoxyadenosine |
| siRNA modification types | 1 | 1 |
| Overall number of modifications | 1 | 1 |
| Position of modifications | 20 | 20 |
| Modification on sugar or base or phosphate | Base | Base |
| SMILES (Click to view structure & nomenclature) |
OCC1OC(CC1O)N1C=NC2=C(NCCNC3=C4N=CN(C5CC(O)C(CO)O5)C4=NC=N3)N=CN=C12 |
OCC1OC(CC1O)N1C=NC2=C(NCCNC3=C4N=CN(C5CC(O)C(CO)O5)C4=NC=N3)N=CN=C12 |
| siRNA Sequence | AUCUGAAGAAGGAGAAAAAA | UUUUUCUCCUUCUUCAGAUA |
| siRNA length base-pair | 20 | 20 |
| siRNA name in paper | VIII | VIII |
| Biological activity | IC-50 = 0.027 nM for target mRNA | |
| Experiment used to check activity | PAGE non-denaturating | |
| Melting temperature (oC) | 61.8 | |
| Target gene | Luciferase gene | |
| siRNA concentration | 0.028 nM | |
| Cell or Organism used | SH-SY5Y and MCF-7 cells | |
| Transfection method | Lipofectamine 2000 | |
| Duration after transfection | 24 Hours | |
| Article title | Functionalization of the 3'-ends of DNA and RNA strands with N-ethyl-N-coupled nucleosides: a promising approach to avoid 3'-exonuclease-catalyzed hydrolysis of therapeutic oligonucleotides |
|
| Reference | 23362010 | |